---
title: "Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299887370.md"
description: "Canaccord Genuity analyst Whitney Ijem maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $442.00. Ijem covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alnylam Pharma, and BioMarin Pharmaceutical. According to TipRanks, Ijem has an average return of 18.9% and a 47.29% success rate on recommended stocks. In addition to Canaccord Genuity, Vertex Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued yesterday. However, today, Barclays maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX)."
datetime: "2026-09-23T11:16:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299887370.md)
  - [en](https://longbridge.com/en/news/299887370.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299887370.md)
generator: "portal-rs"
---

# Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity

Canaccord Genuity analyst Whitney Ijem maintained a Hold rating on Vertex Pharmaceuticals today and set a price target of $442.00.

Ijem covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alnylam Pharma, and BioMarin Pharmaceutical. According to TipRanks, Ijem has an average return of 18.9% and a 47.29% success rate on recommended stocks. 

In addition to Canaccord Genuity, Vertex Pharmaceuticals also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued yesterday. However, today, Barclays maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX).

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [RARE.US](https://longbridge.com/en/quote/RARE.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [2 Healthcare Stocks That Just Delivered Great News for Investors](https://longbridge.com/en/news/300206760.md)
- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria](https://longbridge.com/en/news/299770014.md)
- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)
- [Are Wall Street Analysts Bullish on Vertex Stock?](https://longbridge.com/en/news/296449653.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**